Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($9.21), $6.11 worse than the analyst estimate of ($3.10).Second Quarter 2019 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE